SLRN FINAL DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages SLRN Investors with Substantial Losses to Contact Firm Before Jan. 16th Deadline in Securities Fraud Lawsuit Stemming from Drug Candidate’s Progress
15. Januar 2024 15:04 ET
|
Hagens Berman Sobol Shapiro LLP
SAN FRANCISCO, Jan. 15, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Acelyrin, Inc. (NASDAQ: SLRN) investors who suffered substantial losses to submit your losses now. Class Period: May 4, 2023...
SLRN 6-DAY DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages SLRN Investors with Substantial Losses to Contact Firm Before Jan. 16th Deadline in Securities Fraud Lawsuit
10. Januar 2024 18:49 ET
|
Hagens Berman Sobol Shapiro LLP
SAN FRANCISCO, Jan. 10, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Acelyrin, Inc. (NASDAQ: SLRN) investors who suffered substantial losses to submit your losses now. Class Period: May 4, 2023...
Analyst Says Acelyrin (SLRN) Dosing Errors Create “Too Much Uncertainty,” Securities Class Action Pending - Hagens Berman
07. Januar 2024 10:50 ET
|
Hagens Berman Sobol Shapiro LLP
SAN FRANCISCO, Jan. 07, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Acelyrin, Inc. (NASDAQ: SLRN) investors who suffered substantial losses to submit your losses now. Class Period: May 4, 2023 –...
SLRN 12-DAY DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages SLRN Investors with Substantial Losses to Contact Firm Before Jan. 16th Deadline in Securities Fraud Lawsuit Stemming from Drug Candidate’s Progress
04. Januar 2024 15:01 ET
|
Hagens Berman Sobol Shapiro LLP
SAN FRANCISCO, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Acelyrin, Inc. (NASDAQ: SLRN) investors who suffered substantial losses to submit your losses now. Class Period: May 4,...
Acelyrin (SLRN) Faces Investor Fraud Lawsuit for Allegedly Lying About Drug Candidate’s Progress-Hagens Berman
01. Januar 2024 09:35 ET
|
Hagens Berman Sobol Shapiro LLP
SAN FRANCISCO, Jan. 01, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Acelyrin, Inc. (NASDAQ: SLRN) investors who suffered substantial losses to submit your losses now. Class Period: May 4, 2023 –...
Analyst Says Acelyrin (SLRN) Dosing Errors Create “Too Much Uncertainty,” Securities Class Action Pending - Hagens Berman
29. Dezember 2023 13:50 ET
|
Hagens Berman Sobol Shapiro LLP
SAN FRANCISCO, Dec. 29, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges Acelyrin, Inc. (NASDAQ: SLRN) investors who suffered substantial losses to submit your losses now. Class Period: May 4, 2023 –...
Analyst Says Acelyrin (SLRN) Dosing Errors Create “Too Much Uncertainty,” Securities Class Action Pending - Hagens Berman
22. Dezember 2023 14:22 ET
|
Hagens Berman Sobol Shapiro LLP
SAN FRANCISCO, Dec. 22, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges Acelyrin, Inc. (NASDAQ: SLRN) investors who suffered substantial losses to submit your losses now. Class Period: May 4, 2023 –...
Investors Say Acelyrin (SLRN) Lied About Drug Candidate’s Progress-Hagens Berman
18. Dezember 2023 16:14 ET
|
Hagens Berman Sobol Shapiro LLP
SAN FRANCISCO, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges Acelyrin, Inc. (NASDAQ: SLRN) investors who suffered substantial losses to submit your losses now. Class Period: May 4, 2023 –...
Kaplan Fox & Kilsheimer LLP Reminds Acelyrin Investors of a Class Action Lawsuit and Upcoming Deadline
17. Dezember 2023 08:01 ET
|
Kaplan Fox & Kilsheimer LLP
Kaplan Fox reminds Acelyrin investors of a class action lawsuit and upcoming deadline.
Acelyrin (SLRN) Discloses CRO Errors in Izokibep Program in Wake of Investor Class Action -Hagens Berman
15. Dezember 2023 16:34 ET
|
Hagens Berman Sobol Shapiro LLP
SAN FRANCISCO, Dec. 15, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges Acelyrin, Inc. (NASDAQ: SLRN) investors who suffered substantial losses to submit your losses now. Class Period: May 4, 2023...